Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHanna L. ZiegerPBPeter BorchmannRJRon D. JachimowiczMax Planck Society

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows bridging with glofitamab improves progression-free survival in large B-cell lymphoma, highlighting its potential over conventional treatments.

Key Points

  • Bridging with glofitamab led to an overall response of 69% in patients with large B-cell lymphoma.
  • Cytopenia occurred in 4% of patients using glofitamab, compared to 35% in conventional bridging.
  • Progression-free survival at 90 days was 78% for glofitamab versus 70% for conventional approaches.
  • T-cell exhaustion markers significantly increased in CAR-T cells from patients receiving glofitamab therapy.

Cite This Study

Zieger et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df6ahttps://doi.org/10.1182/blood-2025-3734
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  2. 2Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients2025